Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07441408

Enrollment

2380

Registered

2026-03-02

Start date

2026-12-16

Completion date

2030-03-30

Last updated

2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis

Keywords

LPA1 receptor antagonist, Idiopathic pulmonary fibrosis, Progressive pulmonary fibrosis, Long-term extension, IPF, PPF, IM027068, IM0271015, Follow up

Brief summary

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Interventions

DRUGBMS-986278

Specified dose on specified days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.

Exclusion criteria

* Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation. * Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015. * Exhibit symptoms of heart failure at rest. * History of lung reduction surgery or lung transplant. * Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy. * Other protocol-defined Inclusion/

Design outcomes

Primary

Measure	Time frame
Number of Participants With Treatment Emergent Adverse Events (TEAEs)	Up to Week 100
Number of Participants With Serious Adverse Events (SAEs)	Up to Week 100
Number of Participants With AEs leading to Discontinuation	Up to Week 100
Number of Participants With AEs leading to Deaths	Up to Week 100
Number of Participants With Clinically Significant Laboraty Abnormalities	Up to Week 100
Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities	Up to Week 100
Number of Participants With Clinically Significant Vital Sign Abnormalities	Up to Week 100

Countries

Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Peru, Portugal, South Korea, Spain, Taiwan, United Kingdom, United States

Contacts

CONTACTBMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Clinical.Trials@bms.com855-907-3286

CONTACTFirst line of the email MUST contain NCT # and Site #.

STUDY_DIRECTORBristol-Myers Squibb

Bristol-Myers Squibb

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026